中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

8 records (took 0.017 seconds)

    DEVELOPMENT OF A C-REACTIVE PROTEIN MUTANT WITH IMPROVED THERAPEUTIC BENEFIT IN IMMUNE THROMBOCYTOPENIA AND LUPUS NEPHRITIS
    1.
    发明申请
    DEVELOPMENT OF A C-REACTIVE PROTEIN MUTANT WITH IMPROVED THERAPEUTIC BENEFIT IN IMMUNE THROMBOCYTOPENIA AND LUPUS NEPHRITIS 审中-公开
    在免疫性脑血管病和红斑狼疮中改善治疗效果的C-反应蛋白突变体的发展

    公开(公告)号：WO2009148566A3

    公开(公告)日：2010-02-25

    申请号：PCT/US2009003338

    申请日：2009-06-02

    Applicant: STC UNM ,  DU CLOS TERRY W ,  MOLD CAROLYN

    Inventor： DU CLOS TERRY W ,  MOLD CAROLYN

    IPC: A61K38/16 ,  A61P13/12 ,  A61P19/02

    CPC classification number: A61K38/1745 ,  C07K14/4737

    Abstract: The present invention relates to the use of a mutant CRP molecule in which tyrosine 175 is replaced by leucine (Y175L CRP) or the leucine 176 is replaced by glutamic acid (L176E CRP) for the treatment of various disease states and conditions associated with SLE, including lupus of the skin (discoid), systemic lupus of the joints, lungs and kidneys, hematological conditions including hemolytic anemia and low lymphocyte counts, lymphadenopathy and CNS effects, including memory loss, seizures and psychosis, among numerous others as otherwise disclosed herein. In another aspect of the invention, the reduction in the likelihood that a patient who is at risk for an outbreak of a disease state or condition associated with SLE will have an outbreak is an additional aspect of the present invention. The present invention relates to the use of mutant Y175L CRP or L176E CRP in the treatment of a number of disease states or conditions that occur secondary to systemic lupus SLE. The present invention also relates to the treatment of immune thrombocytopenic purpura. Pharmaceutical compositions are also disclosed based these mutant CRP molecules.

    Abstract translation: 本发明涉及使用由亮氨酸（Y175L CRP）代替酪氨酸175或用谷氨酸（L176E CRP）代替的亮氨酸176用于治疗与SLE有关的各种疾病状态和病症的突变型CRP分子， 包括皮肤（盘状）的狼疮，关节，肺和肾的系统性红斑狼疮，包括溶血性贫血和低淋巴细胞计数的血液学病症，淋巴结病和CNS作用，包括记忆丧失，癫痫发作和精神病，其他如本文另有公开。 在本发明的另一方面，降低与SLE相关的疾病状态或病症发生风险的患者将发生爆发的可能性是本发明的另外的方面。 本发明涉及突变型Y175L CRP或L176E CRP在治疗多发于系统性红斑狼疮SLE继发性疾病状态或病症中的应用。 本发明还涉及免疫性血小板减少性紫癜的治疗。 还公开了基于这些突变型CRP分子的药物组合物。

    SUPPRESSIVE MACROPHAGES, C-REACTIVE PROTEIN AND THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS AND IMMUNE THROMBOCYTOPENIC PURPURA
    3.
    发明专利
    SUPPRESSIVE MACROPHAGES, C-REACTIVE PROTEIN AND THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS AND IMMUNE THROMBOCYTOPENIC PURPURA 未知

    公开(公告)号：CA2670125A1

    公开(公告)日：2008-05-15

    申请号：CA2670125

    申请日：2007-11-06

    Applicant: STC UNM

    Inventor： DU CLOS TERRY W ,  MOLD CAROLYN

    IPC: A61K35/14 ,  A61K35/15 ,  A61K35/28

    Abstract: The present invention relates to the use of suppressive macrophage or den dritic cells (activated with C-reactive protein or CRP-related compounds), f or the treatment of various disease states and conditions associated with im mune thrombocytopenic purpura (ITP) and/or systemic lupus erythematosus (SLE ), including lupus of the skin (discoid), systemic lupus of the joints, lung s and kidneys, hematological conditions including hemolytic anemia and low l ymphocyte counts, lymphadenopathy and CNS effects, including memory loss, se izures and psychosis, among numerous others as otherwise disclosed herein. I n another aspect of the invention, the reduction in the likelihood that a pa tient who is at risk for an outbreak of a disease state or condition associa ted with systemic lupus erythematosus or ITP will have an outbreak is an add itional aspect of the present invention. In the case of ITP, methods of the present invention are used to increase platelet counts in the treated patien t. In addition, in the case of ITP, the present invention relates to the use of CRP or a CRP-related compound in the absence of suppressive macrophages for the treatment of ITP.

    SUPPRESSIVE MACROPHAGES, C-REACTIVE PROTEIN AND THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS AND IMMUNE THROMBOCYTOPENIC PURPURA
    4.
    发明申请
    SUPPRESSIVE MACROPHAGES, C-REACTIVE PROTEIN AND THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS AND IMMUNE THROMBOCYTOPENIC PURPURA 审中-公开
    抑制性巨噬细胞，C反应蛋白和系统性红斑狼疮治疗和免疫性血栓形成性PURPURA

    公开(公告)号：WO2008057505A3

    公开(公告)日：2008-08-28

    申请号：PCT/US2007023311

    申请日：2007-11-06

    Applicant: STC UNM ,  DU CLOS TERRY W ,  MOLD CAROLYN

    Inventor： DU CLOS TERRY W ,  MOLD CAROLYN

    IPC: A61K35/14

    CPC classification number: A61K35/15 ,  A61K35/28 ,  A61K38/1745 ,  A61K2300/00

    Abstract: The present invention relates to the use of suppressive macrophage or dendritic cells (activated with C-reactive protein or CRP-related compounds), for the treatment of various disease states and conditions associated with immune thrombocytopenic purpura (ITP) and/or systemic lupus erythematosus (SLE), including lupus of the skin (discoid), systemic lupus of the joints, lungs and kidneys, hematological conditions including hemolytic anemia and low lymphocyte counts, lymphadenopathy and CNS effects, including memory loss, seizures and psychosis, among numerous others as otherwise disclosed herein. In another aspect of the invention, the reduction in the likelihood that a patient who is at risk for an outbreak of a disease state or condition associated with systemic lupus erythematosus or ITP will have an outbreak is an additional aspect of the present invention. In the case of ITP, methods of the present invention are used to increase platelet counts in the treated patient. In addition, in the case of ITP, the present invention relates to the use of CRP or a CRP-related compound in the absence of suppressive macrophages for the treatment of ITP.

    Abstract translation: 本发明涉及抑制性巨噬细胞或树突状细胞（用C反应蛋白或CRP相关化合物活化）用于治疗与免疫血小板减少性紫癜（ITP）和/或系统性红斑狼疮相关的各种疾病状态和病症 （SLE），包括皮肤（盘状）的狼疮，关节，肺和肾的系统性红斑狼疮，血液病症，包括溶血性贫血和低淋巴细胞计数，淋巴结病和CNS作用，包括记忆丧失，癫痫发作和精神病， 本文另有公开。 在本发明的另一方面，减少与系统性红斑狼疮或ITP相关的疾病状态或疾病爆发危险的患者将发生爆发的可能性是本发明的另外的方面。 在ITP的情况下，本发明的方法用于增加治疗患者的血小板计数。 此外，在ITP的情况下，本发明涉及在不存在抑制性巨噬细胞用于治疗ITP的情况下使用CRP或CRP相关化合物。

    C-REACTIVE PROTEIN AND ITS USE TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS AND RELATED CONDITIONS
    5.
    发明申请
    C-REACTIVE PROTEIN AND ITS USE TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS AND RELATED CONDITIONS 审中-公开
    C-反应蛋白及其用于治疗系统性红斑狼疮及相关病症

    公开(公告)号：WO2007050661A3

    公开(公告)日：2007-09-20

    申请号：PCT/US2006041583

    申请日：2006-10-26

    Applicant: STC UNM ,  DU CLOS TERRY W ,  MOLD CAROLYN

    Inventor： DU CLOS TERRY W ,  MOLD CAROLYN

    IPC: C07K14/435

    CPC classification number: A61K38/1709

    Abstract: The present invention relates to the use of C-reactive protein, its mutants, metabolites and polypeptides and related compounds thereof for the treatment of various disease states and conditions associated with systemic lupus erythematosus (SLE), including lupus of the skin (discoid), systemic lupus of the joints, lungs and kidneys, hematological conditions including hemolytic anemia and low lymphocyte counts, lymphadenopathy and CNS effects, including memory loss, seizures and psychosis, among numerous others as otherwise disclosed herein, hi another aspect of the invention, the reduction in the likelihood that a patient who is at risk for an outbreak of a disease state or condition associated with systemic lupus erythematosus will have an outbreak is an additional aspect of the present invention.

    Abstract translation: 本发明涉及C-反应蛋白，其突变体，代谢物和多肽及其相关化合物用于治疗与系统性红斑狼疮（SLE）有关的各种疾病状态和病症（包括皮肤的狼疮（盘状））的用途， 在本发明的另一方面中，关节，肺和肾的系统性红斑狼疮，包括溶血性贫血和低淋巴细胞计数的淋巴细胞病症，淋巴结病和CNS作用（包括记忆丧失，癫痫发作和精神病） 在有可能爆发与系统性红斑狼疮相关的疾病状态或病症的患者发生暴发的可能性是本发明的另一方面。

    SUPPRESSIVE MACROPHAGES, C-REACTIVE PROTEIN AND THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS AND IMMUNE THROMBOCYTOPENIC PURPURA
    6.
    发明公开
    SUPPRESSIVE MACROPHAGES, C-REACTIVE PROTEIN AND THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS AND IMMUNE THROMBOCYTOPENIC PURPURA 审中-公开
    抑制巨噬细胞，C反应蛋白和免疫治疗系统性红斑狼疮和血小板减少性紫癜

    公开(公告)号：EP2097087A4

    公开(公告)日：2013-01-02

    申请号：EP07867365

    申请日：2007-11-06

    Applicant: STC UNM

    Inventor： DU CLOS TERRY W ,  MOLD CAROLYN

    IPC: A61K35/14 ,  A61K35/12 ,  A61K35/28 ,  A61K38/17 ,  A61P37/02

    CPC classification number: A61K35/15 ,  A61K35/28 ,  A61K38/1745 ,  A61K2300/00

    Abstract: The present invention relates to the use of suppressive macrophage or dendritic cells (activated with C-reactive protein or CRP-related compounds), for the treatment of various disease states and conditions associated with immune thrombocytopenic purpura (ITP) and/or systemic lupus erythematosus (SLE), including lupus of the skin (discoid), systemic lupus of the joints, lungs and kidneys, hematological conditions including hemolytic anemia and low lymphocyte counts, lymphadenopathy and CNS effects, including memory loss, seizures and psychosis, among numerous others as otherwise disclosed herein. In another aspect of the invention, the reduction in the likelihood that a patient who is at risk for an outbreak of a disease state or condition associated with systemic lupus erythematosus or ITP will have an outbreak is an additional aspect of the present invention. In the case of ITP, methods of the present invention are used to increase platelet counts in the treated patient. In addition, in the case of ITP, the present invention relates to the use of CRP or a CRP-related compound in the absence of suppressive macrophages for the treatment of ITP.

Patent Agency Ranking